A Study to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease

  • STATUS
    Recruiting
Send
Updated on 19 February 2024

Summary

BAN2401 is an investigational study drug which is being studied in people who have early AD (Alzheimer's disease), with mild cognitive (thinking) impairment or mild dementia. People with AD have a build-up of abnormal protein known as amyloid in their brains.  This build up may lead to impairment in memory or thinking.  
BAN2401 is a monoclonal (single) antibody.  Antibodies are proteins produced by the immune system that bind to foreign substances in the body called antigens.  BAN2401 binds to amyloid in the brain in patients with AD and has been shown to reduce the amount of this abnormal protein.   
The purpose of this study is to assess the safety (symptoms and medical problems you may experience - known as side effects) and efficacy (how much the study drug improves symptoms and reduces amyloid in the brain) of the study drug in patients who have early AD.
 
There have been three studies of BAN2401.  About 688 subjects with AD have been treated with BAN2401 so far.

Description

 

FAQ


Details
Condition ,Alzheimer's,Early Alzheimer's Disease,amyloid,mild cognitive impairment,Alzheimer's disease,amyloid therapy
Age 50years - 90years
Clinical Study IdentifierTX10586
Last Modified on19 February 2024

Eligibility

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact label
Race
Ethnicity
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.